Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

• MEDI-507 (Drug)

Primary outcomes

• To determine the maximum tolerated dose (MTD) or the optimal biological dose
• (OBD) of MEDI-507 based on safety and tolerability of MEDI-507 in patients with
• CD-2 positive lymphoproliferative disorders.

Sex: All, ages: 18 Years to any

Individuals may be eligible for this study if they are 18 years of age or older and:

* Have one of the following types of T-Cell Lymphoproliferative disorders such as Cutaneous T-cell Lymphoma (CTCL), Peripheral T-cell Lymphoma (PCTL), Large Cell Lymphoma (LGL), or Adult T-cell Lymphoma (ATL). Patients should have disease that is resistant or refractory to the front-line therapy, except ATL patients for whom there is no standard therapy.
* At least 30% of tumor cells must be CD2 positive.
* Karnofsky Performance status of greater than or equal to 70% (able to care for themselves; but unable to carry on normal activity or to do active work).
* At least 3 weeks must have passed since prior systemic cytotoxic chemotherapy, prolonged or cytolytic steroid therapy or major surgery, and all treatment-related toxicities must have resolved prior to the first MEDI-507 administration (except thrombocytopenia).
* Have no prior treatment with MEDI-507.

• Luz Hammershaimb, MD, Study director, MedImmune LLC